Aratana Therapeutics, Inc. (PETX): Ernst Heinen , Chief Development Officer of Aratana Therapeutics, Inc. sold 15,000 shares on Jun 10, 2016. The Insider selling transaction was reported by the company on Jun 13, 2016 to the Securities and Exchange Commission. The shares were sold at $6.72 per share for a total value of $100,861.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 2, 2016, Craig A Tooman (CHIEF FINANCIAL OFFICER) sold 2,806 shares at $3.36 per share price.On Jul 17, 2015, Ernst Heinen (Chief Development Officer) sold 15,000 shares at $17.06 per share price.Also, On Apr 28, 2015, Linda Rhodes (CHIEF SCIENTIFIC OFFICER) sold 15,000 shares at $15.28 per share price.On Mar 6, 2015, Vort John Vander (director) sold 6,137 shares at $20.01 per share price.
Shares of Aratana Therapeutics Inc (PETX) ended Friday, Jun 10, 2016 session in red amid volatile trading. The shares closed down -0.4 points or -5.63% at $6.7 with 4,75,254 shares getting traded. Post opening the session at $7.02, the shares hit an intraday low of $6.6 and an intraday high of $7.02 and the price vacillated in this range throughout the day. The company has a market cap of $237 M and the number of outstanding shares has been calculated to be 3,53,47,186 shares. The 52-week high of Aratana Therapeutics Inc is $19.9896 and the 52-week low is $2.56.
Company has been under the radar of several Street Analysts.Aratana Therapeutics Inc is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 11 from a previous price target of $12 . The Rating was issued on Mar 16, 2016.
Aratana Therapeutics Inc. is a pet therapeutics company focused on licensing developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions such as pain and inflammation stimulation of appetite cancer and other serious diseases for dogs and cats. These product candidates are in various stages of development for the treatment of cats or dogs or both. The Company’s target indications include pain and inflammation associated with osteoarthritis inappetence post-operative pain lymphoma osteosarcoma atopic dermatitis ocular herpes and feline immunodeficiency virus. The Company’s most advanced products from a development and commercialization perspective AT-004 and AT-005 are monoclonal antibodies (MAbs) for treating lymphoma in dogs.